Naik R B, Chakraborty J, English J, Marks V, Slapak M, Lee H A
Br Med J. 1980 Jun 7;280(6228):1337-40. doi: 10.1136/bmj.280.6228.1337.
Ten patients with stable renal function two years after transplantation had their sole immunosuppressive treatment (oral prednisolone 10 mg daily) withdrawn by reducing the daily dose by 1 mg at monthly intervals. Plasma prednisolone concentration, cortisol concentration, creatinine clearance, and serum creatinine concentration were measured in all patients, and the adrenal response to corticotrophin was determined in five by measuring plasma cortisol concentrations before and after tetracosactrin injection. No episodes of rejection occurred in patients taking over 7 mg prednisolone daily. Although three patients apparently required only minimal immunosuppressive treatment (less than 5 mg daily) the remainder suffered episodes of rejection at daily doses below 7 mg. There was a tenuous association between rejection and low plasma cortisol concentration, but neither the pattern of plasma prednisolone concentrations nor the response to tetracosactrin were related to episodes of rejection. Reducing the daily dose of oral prednisolone to under 7 mg should not be attempted in patients with renal transplants unless there are extenuating circumstances.
10名移植后肾功能稳定两年的患者,通过每月将每日剂量减少1毫克的方式,停用了他们唯一的免疫抑制治疗(每日口服泼尼松龙10毫克)。对所有患者测量了血浆泼尼松龙浓度、皮质醇浓度、肌酐清除率和血清肌酐浓度,并通过测量注射替可克肽前后的血浆皮质醇浓度,对5名患者的肾上腺对促肾上腺皮质激素的反应进行了测定。每日服用泼尼松龙超过7毫克的患者未发生排斥反应。虽然3名患者显然仅需要最低限度的免疫抑制治疗(每日少于5毫克),但其余患者在每日剂量低于7毫克时发生了排斥反应。排斥反应与低血浆皮质醇浓度之间存在微弱关联,但血浆泼尼松龙浓度模式和对替可克肽的反应均与排斥反应无关。除非有情有可原的情况,肾移植患者不应尝试将口服泼尼松龙的每日剂量减至7毫克以下。